2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed Download Presentation Webcast Excel
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® Download Presentation Webcast Excel
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study Download Presentation Webcast Excel
2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA Download Presentation Webcast Excel
2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance Download Presentation Webcast Excel
Regulatory 2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021 Download Presentation Webcast Excel
Regulatory 2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm Download Presentation Webcast Excel
Regulatory 2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB Download Presentation Webcast Excel
Regulatory 2021-04-09 | Issue and repurchase of series C shares for share saving program Download Presentation Webcast Excel
Regulatory 2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB Download Presentation Webcast Excel
Regulatory 2021-03-17 | Notice of extraordinary general meeting in Ascelia Pharma Download Presentation Webcast Excel
2021-03-02 | Ascelia Pharma opens US office in preparation for Mangoral launch Download Presentation Webcast Excel
2021-01-12 | Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy Download Presentation Webcast Excel
Regulatory 2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral Download Presentation Webcast Excel
Regulatory 2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent Download Presentation Webcast Excel
2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU Download Presentation Webcast Excel
Regulatory 2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually Download Presentation Webcast Excel
2020-09-30 | Invitation to Ascelia Pharma’s virtual Capital Markets Day Download Presentation Webcast Excel
2020-06-09 | Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day Download Presentation Webcast Excel
